Xiaohua Chen

Xiaohua Chen

Auto-generated profile, based on publicly available information

Xiaohua Chen

Division of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TTThuy-Anh Tran
Thuy-Anh Tran
BKBryan Kramer
Bryan Kramer
YSYoung-Jun Shin
Young-Jun Shin
PVPureza Vallar
Pureza Vallar
PBP. Douglas Boatman
P. Douglas Boatman
GSGraeme Semple
Graeme Semple
The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described. Detailed profiling of a number of analogues resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor. In our hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clinical compound NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays. 5c had an excellent PK profile across species. Enterohepatic recirculation most probably contributes to a concentration–time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio. Following the identification of an acceptable solid form, 5c was selected for further development for the treatment of PAH.

1 March 2020 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
JQJufeng Qin
Jufeng Qin
GZGuofeng Zhou
Guofeng Zhou
XCXiaohua Chen
Xiaohua Chen
Imaging manifestations of bladder paraganglioma Jufeng Qin, Guofeng Zhou, Xiaohua Chen

7 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
MLMark T. Vander Lugt
Mark T. Vander Lugt
XCXiaohua Chen
Xiaohua Chen
MEMaria L. Escolar
Maria L. Escolar
BCBeth A. Carella
Beth A. Carella
JBJessie L. Barnum
Jessie L. Barnum
PSPaul Szabolcs
Paul Szabolcs
Children with many inherited nonmalignant disorders can be cured or their condition alleviated by hematopoietic stem cell transplantation (HSCT). Umbilical cord blood (UCB) units are a rapidly available stem cell source and offer great flexibility in HLA matching, allowing nearly uniform access to HSCT. Although reduced-intensity conditioning (RIC) regimens promise decreased treatment-related morbidity and mortality, graft failure and infections have limited their use in chemotherapy-naive patients. We prospectively evaluated a novel RIC regimen of alemtuzumab, hydroxyurea, fludarabine, melphalan, and thiotepa with a single-unit UCB graft in 44 consecutive patients with inborn errors of metabolism, immunity, or hematopoiesis. In addition, 5% of the UCB graft was re-cryopreserved and reserved for cord donor leukocyte infusion (cDLI) posttransplant. All patients engrafted at a median of 15 days posttransplant, and chimerism was >90% donor in the majority of patients at 1-year posttransplant with only 1 secondary graft failure. The incidence of grade II to IV graft-versus-host disease (GVHD) was 27% (95% confidence interval [CI], 17-43) with no extensive chronic GVHD. Overall survival was 95% (95% CI, 83-99) and 85% (95% CI, 64-93) at 1 and 5 years posttransplant, respectively. No significant end-organ toxicities were observed. The use of cDLI did not affect GVHD and showed signals of efficacy for infection control or donor chimerism. This RIC transplant regimen using single-unit UCB graft resulted in outstanding survival and remarkably low rates of graft failure. Implementation of the protocol not requiring pharmacokinetic monitoring would be feasible and applicable worldwide for children with inherited disorders of metabolism, immunity, or hematopoiesis. This trial was registered at www.clinicaltrials.gov as #NCT01962415.

25 April 2013 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
FLFengsheng Li
Fengsheng Li
LGLing Gao
Ling Gao
ZWZhidong Wang
Zhidong Wang
Bo DongBo Dong
Bo Dong
TYTao Yan
Tao Yan
XCXiaohua Chen
Xiaohua Chen
In the present study, the effect of radiation on the invasion of the pulmonary adenocarcinoma cell line, A549, was investigated. Invasion of A549 cells irradiated with 2 and 4 Gy doses of γ‑ray was detected using the transwell Matrigel invasion assay. Levels of matrix metalloproteinase 2 (MMP‑2) and phosphorylated signal transducer and activator of transcription 3 (STAT3) were detected by reverse transcription PCR (RT-PCR) and/or immunoblotting. The enzyme activity of MMP‑2 was examined by gelatin zymography. Results demonstrated that the invasion of A549 cells was significantly enhanced by γ‑ray radiation at doses of 2 or 4 Gy. In addition, exposure to radiation was found to promote transcriptional expression of MMP‑2 and increase MMP‑2 enzyme activity. Irradiation activated the phosphorylation of STAT3 and promoted the nuclear localization of STAT3. The blockage of STAT3 phosphorylation using a specific inhibitor (AG490) suppressed the irradiation‑induced elevation of MMP‑2 expression, enzyme activity and invasion of A549 cells. Finally, the expression of vascular endothelial growth factor (VEGF) was found to be upregulated by radiation, which was associated with the activation of STAT3. Results of the current study indicate that irradiation leads to activation of STAT3 and translocation to the nucleus, leading to activation of VEGF and MMP‑2 transcription, resulting in the increased invasion of A549 cells.

8 July 2023 in Cytotherapy
Verified
Journal Article
Closed access
MWMike Winstead
Mike Winstead
MHMemphis Hill
Memphis Hill
ZAZarreen Amin
Zarreen Amin
MLMark Vander Lugt
Mark Vander Lugt
XCXiaohua Chen
Xiaohua Chen
PSPaul Szabolcs
Paul Szabolcs

13 February 2012 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
LSLinlin Song
Linlin Song
MZMeng Zhuo
Meng Zhuo
YTYuyan Tang
Yuyan Tang
XCXiaohua Chen
Xiaohua Chen
YYYongsheng Yu
Yongsheng Yu
GZGuoqing Zang
Guoqing Zang
Cluster of differentiation (CD)8+ cytotoxic T lymphocytes (CTLs) have a key role in the elimination of hepatitis B virus (HBV)-infected cells. Ubiquitin (Ub) functions as a marker for protein degradation, which may promote the generation of peptides appropriate for major histocompatibility complex class I presentation, while the HBV core antigen (HBcAg) possesses marked immunogenic properties. However, it remains to be elucidated whether Ub-modified HBcAg is able to effectively elicit significant CD8+ CTL activity. In order to address this issue, a prokaryotic vector was constructed to express the Ub-HBcAg-cytoplasmic transduction peptide (CTP). The fusion protein was successfully expressed and subsequently pulsed into bone-marrow-derived dendritic cells (DCs). It was confirmed that with assistance from the cell‑penetrating properties of CTP, the fusion protein was able to directly penetrate into the cytoplasm of DCs. The results revealed that the Ub-HBcAg-CTP fusion protein not only increased the expression of surface molecules in DCs and cytokine secretion from proliferating T cells, but also induced T cells to differentiate into specific CTLs and enhanced their antiviral ability. In conclusion, the Ub-HBcAg-CTP fusion protein promoted DC maturation, enhanced the presentation of targeting antigens and efficiently induced HBcAg‑specific CTL immune responses in vitro.